Skip to main content
MedPathMedPath Home
Clinical Trials/PER-014-03
PER-014-03
Completed
Phase 1

A MULTICIENTRIC, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK-0767 TO PATIENTS WITH TYPE 2 DIABETES THAT PRESENT INACCURATE GLYCEMIC CONTROL IN THE COMBINED THERAPY OF METFORMIN AND SULFONILUREA.

MERCK SHARP & DOHME PERU S.R.L.,0 sites0 target enrollmentMarch 12, 2003
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Not specified
Sponsor
MERCK SHARP & DOHME PERU S.R.L.,
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 12, 2003
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
MERCK SHARP & DOHME PERU S.R.L.,

Eligibility Criteria

Inclusion Criteria

  • •Age\> 21 and \<78 years.
  • •In stable doses of metformin and sulfonylurea for at least 2
  • •weeks before Visit 2 / Week \-6\.
  • •Understanding of study procedures and agreement of
  • •participate in the study through informed consent

Exclusion Criteria

  • •Patients with a history of type 1 diabetes mellitus and / or history
  • •of ketoacidosis and / or C\-peptide \<0\.8 ng / mL (\<0\.26 nmol / L).
  • •Patients with the following treatments for diabetes during the
  • •8 weeks prior to Visit 1\.
  • •Patients with a history of allergy, intolerance or hypersensitivity to troglitazone, rosiglitazone, pioglitazone or other PPAR\-agonists and including a history of elevated liver function test, jaundice, or hepatotoxicity associated with these treatments.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Not Applicable
A RANDOMIZED, MULTICENTRE, DOUBLE BLIND, PLACEBO CONTROLLEDSTUDY EVALUATING THE EFFICACY OF VARENICLINE IN CESSATION OFORAL TOBACCO USECessation of oral smokeless tobacco use in current non-smokers.MedDRA version: 9.1Level: LLTClassification code 10053325Term: Smoking cessation therapy
EUCTR2008-000546-31-SEPfizer Ltd, Ramsgate Road,Sandwich,Kent CT13 9NJ432
Recruiting
Phase 3
A clinical trial to assess the effect of Linaclotide in patients with chronic constipatioHealth Condition 1: K590- Constipation
CTRI/2023/03/050482Dr Reddys Laboratories Limited
Active, not recruiting
Not Applicable
Sleep efficiency assessed by Polysomnography (PSG sleep lab testing) in advanced Parkinson's diseaseAdvanced Parkinson's DiseaseMedDRA version: 14.1Level: PTClassification code 10061536Term: Parkinson's diseaseSystem Organ Class: 10029205 - Nervous system disordersTherapeutic area: Diseases [C] - Nervous System Diseases [C10]
EUCTR2011-000056-42-GBCB Celltech, UK - Registered Branch of UCB Pharma SA
Active, not recruiting
Phase 1
EXPLORATORY EFFICACY AND SAFETY STUDY OF GLENZOCIMAB IN SARS-Cov-2-RELATED ACUTE RESPIRATORY DISTRESS SYNDROME
EUCTR2020-002733-15-FRACTICOR BIOTECH40
Active, not recruiting
Phase 1
A vaccine and a device used together to treat women with precancerous cells on the cervix caused by human papillomavirus (HPV).
EUCTR2016-002761-63-SKInovio Pharmaceuticals, Inc.198